Search
Theriva Biologics Inc
TOVXAdd to Watchlist
0.235USD
+0.004+1.73%
Close 09-22 16:00（ET）
10.78MMarket Cap
LossP/E TTM
After-hours 16:10 (ET)0.235USD0.000
After-hours 16:10 (ET)Theriva Biologics Inc (TOVX) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Theriva Biologics Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
2.500USD+970.66%
TOVX Analyst Recommendation Trends
In the current month, TOVX has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TOVX average Analyst price target in the last month is 2.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
2
2
2
2
1
1
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
TOVX Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, TOVX EPS is projected to reach -0.060 in FY2026Q3, following reported EPS of -0.070 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.43
-0.05
-0.05
-0.06
-0.06
Actual
-0.12
-0.05
-0.07
--
--
Surprise
+72.47%
+0.46%
-40.20%
--
--
FAQs
What is Theriva Biologics Inc's price target?
Analysts forecast that Theriva Biologics Inc's price target is USD 2.50, with the highest forecast at USD 4.00 and the lowest forecast at USD 1.00.
How have Theriva Biologics IncTOVX's recent earnings per share performed?
The market expectation was USD -0.07, while Theriva Biologics IncTOVX's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for Theriva Biologics Inc?
Based on the ratings of Theriva Biologics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.